A phase 3 clinical trial has demonstrated 28.7% weight loss over 68 weeks with a new drug called retatrutide. The trial also showed substantial relief from knee osteoarthritis pain — an unexpected secondary finding.
But weight loss figures rarely tell the full story. Below is a detailed breakdown of how retatrutide works, what the trial data actually show, and how it compares to existing medications on both efficacy and safety.
Table of Contents
- A new approach
- The new trial
- Comparison With Other Medications
- Side Effects and Safety
- Retatrutide vs Tirzepatide: What's the Real Comparison?
- Conclusion
- Reference List
A New Approach
Retatrutide is a complex drug. It is a triple agonist — meaning it targets three distinct receptor classes simultaneously:
- Glucagon-like peptide-1 (GLP-1)
- Gastric inhibitory polypeptide (GIP)
- Glucagon receptor agonists
GLP-1: The Foundation
GLP-1 is the best-understood of the three. The most widely known drug targeting this receptor is Ozempic (semaglutide). GLP-1 medications have been used clinically to treat type 2 diabetes since 2005 [1].
The key pharmacological challenge was extending the peptide's duration of action. Endogenous GLP-1 is rapidly degraded by the DPP-4 enzyme, giving it a half-life of only 2 minutes in the body [1].
This extremely short half-life explains why supplements claiming to boost GLP-1 are largely ineffective — even if they temporarily raise circulating levels, the peptide is cleared too quickly to produce meaningful effects.
The breakthrough came from an unexpected source: the venom of the Gila monster. Researchers discovered a structurally similar compound called exendin-4, which resists enzymatic breakdown and binds to the same receptors as GLP-1 [2].
This finding accelerated drug development, progressing from:
- Twice-daily injections (e.g., Byetta®)
- To once-weekly formulations like Bydureon® [1]
As clinical use expanded, researchers noted that GLP-1 medications produced meaningful weight loss alongside blood glucose control — an effect that became a primary research target in its own right.
How GLP-1 Promotes Weight Loss
The weight-loss mechanisms are multifactorial. GLP-1 receptor agonists:
- Stimulate insulin release in response to meals
- Act on brain receptors to increase satiety and suppress appetite
- Slow gastric emptying, prolonging feelings of fullness
- Alter reward pathways, reducing the drive to eat for pleasure rather than hunger [1][3][4]
This last mechanism — often called "reward-hacking" — is particularly significant. GLP-1 receptor activation has been shown to reduce hedonic eating, meaning food cravings decrease even in the absence of hunger [4].
GIP: Dual-Agonist Strategy
Building on GLP-1's success, researchers explored what additional receptor targets might further enhance weight loss.
Gastric inhibitory polypeptide (GIP) emerged as a promising candidate. Like GLP-1, GIP stimulates insulin release in response to ingested nutrients [5].
The combination of GLP-1 + GIP forms the basis of tirzepatide, a dual-agonist medication. Early trials demonstrated that this combination offered greater weight loss than GLP-1 medications alone.
Glucagon Receptor: The Third Arm
Retatrutide extends this strategy further by incorporating a third receptor target: glucagon.
Glucagon has a counterintuitive metabolic profile. On one hand, it stimulates the liver to release glucose and raise blood sugar — which historically made glucagon agonism problematic for treating type 2 diabetes [6].
On the other hand, glucagon receptor activation also:
- Increases energy expenditure
- Promotes fat breakdown (lipolysis)
- Inhibits fat formation (lipogenesis) [6]
The hypothesis underlying retatrutide was that pairing glucagon signalling with GLP-1 and GIP could amplify fat loss without producing clinically significant blood sugar elevation — since GLP-1 and GIP provide an insulin-stimulating counterbalance to glucagon's glucose-raising effects [7].
The evidence suggests this hypothesis holds up. Combining all three receptor targets allows for synergistic metabolic effects, while the co-agonism of GLP-1 and GIP buffers the blood-glucose–raising action of glucagon [7].
This is the three-pronged mechanism of retatrutide.
The New Trial
Mechanistic plausibility aside, what does the clinical trial evidence show — and how does the safety profile hold up?
Phase 1 and 2 Results
Early clinical data were encouraging. A phase 1 study showed clinically meaningful reductions in both blood glucose and body weight [8].
A phase 2 trial raised some safety questions, including a possible signal for cardiac arrhythmias at certain doses — a finding discussed further below [13].
Phase 3 Trial Overview
The pivotal phase 3 trial enrolled 445 overweight or obese adults without diabetes who had knee osteoarthritis [9].
Participants were randomised to:
- 9 mg or 12 mg of retatrutide (weekly subcutaneous injection)
- Or placebo
- Duration: 68 weeks
Weight Loss Results
-
12 mg retatrutide group:
- Average weight loss: 28.7%, or approximately 32 kg / 71 lbs
-
9 mg group:
- Weight loss: 26.4%
-
Placebo group:
- Weight loss: 2.1% [9]
Pain Reduction (WOMAC Score)
Alongside weight reduction, osteoarthritis pain improved substantially across retatrutide groups — likely a consequence of reduced mechanical load on the knee joint.
- Retatrutide groups: approximately 75% reduction in WOMAC pain score
- Placebo group: 40.3% reduction [9]
The placebo group's 40.3% pain reduction is a reminder that pain outcomes are particularly susceptible to placebo effects, regression to the mean, and lifestyle factors co-occurring with trial participation. The retatrutide advantage is still substantial, but the placebo response is worth noting.
Comparison With Other Medications
Semaglutide (Ozempic / Wegovy)
- Trial duration: 68 weeks
- ~15% average weight loss
- In overweight or obese participants without diabetes [10]
Tirzepatide (Mounjaro / Zepbound)
- Trial duration: 72 weeks
- Highest dose (15 mg): ~21% average weight loss
- 2,539 participants without diabetes [11]
Takeaway
Headline efficacy numbers place retatrutide ahead of both semaglutide and tirzepatide. However, efficacy figures alone do not determine clinical suitability — the side-effect profile matters equally.
Side Effects and Safety
The safety and tolerability profile of retatrutide is where the picture becomes more nuanced — and where the comparison with existing options is most clinically important.
Discontinuation Rates
- Retatrutide 12 mg: 18.2% discontinued
- Retatrutide 9 mg: 12.2%
- Placebo: 4% [9]
For comparison:
- Semaglutide: 4.5% discontinued [10]
- Tirzepatide: ~7% discontinued at highest dose [11]
The 18.2% discontinuation rate for 12 mg retatrutide is markedly higher than for either comparator.
Trial authors noted that discontinuation correlated with baseline BMI: participants with lower BMI were more likely to drop out, sometimes because of excessive weight loss. Among those with BMI ≥35, the discontinuation rate fell to 12.1% [9] — still considerably higher than tirzepatide's 7%.
Diarrhea
Gastrointestinal side effects are common to all GLP-1/GIP receptor agonists.
- Retatrutide:
- 9 mg: 34.7%
- 12 mg: 33.1%
- Placebo: 13.4% [9]
Compare that to:
- Semaglutide: 31.5% [10]
- Tirzepatide: 23% at highest dose [11]
Tirzepatide shows lower gastrointestinal side-effect rates than either semaglutide or retatrutide at comparable doses.
Dysesthesia: A Notable Red Flag
Dysesthesia is a sensory disorder causing pain, itching, tingling, or burning sensations when the skin is touched. It is an uncommon side effect not typically associated with semaglutide or tirzepatide.
Reported rates in the retatrutide trial:
- 9 mg: 8.8%
- 12 mg: 20.9%
- Placebo: 0.7% [9]
For comparison:
- Tirzepatide: 0.4% across two major trials [12]
A rate of 20.9% at the 12 mg dose — compared to 0.4% with tirzepatide — is a substantial difference. Most cases in the retatrutide trial were reported as mild and rarely led to discontinuation [9], but the signal is clinically significant and warrants monitoring in any future approval.
Cardiac Arrhythmias: An Unresolved Signal
The phase 2 trial of retatrutide identified elevated rates of heart rhythm abnormalities at certain doses [13].
Full phase 3 cardiac safety data have not yet been published. Whether this signal persists or diminishes at the approved dose range remains an open question — and one regulators will scrutinise closely before any approval decision.
Retatrutide vs Tirzepatide: What's the Real Comparison?
The headline numbers suggest a large gap:
- Retatrutide (12 mg): 28.7% weight loss
- Tirzepatide (15 mg): 20.9% weight loss
However, this is not a fair head-to-head comparison — and the distinction matters.
The 28.7% figure for retatrutide is based on the efficacy estimand: a statistical approach that models outcomes as if all participants had completed the full protocol without discontinuation. In other words, it answers the question: "How much weight would participants have lost if they had stayed on the drug and tolerated it perfectly?"
In clinical practice, not every patient will. The higher discontinuation rate for retatrutide (18.2% vs ~7% for tirzepatide) is real-world data that the efficacy estimand does not capture.
The treatment-regimen estimand (also called the intention-to-treat analysis) is generally more informative for real-world clinical relevance, because it accounts for participants who discontinued.
Under this more conservative analysis:
- Retatrutide (12 mg): 23.7% weight loss
- Tirzepatide (15 mg): 20.9% [9][11]
The gap narrows considerably — from approximately 8 percentage points to approximately 3 — once real-world adherence is factored in. And that 3-percentage-point difference must be weighed against retatrutide's higher discontinuation rate, higher dysesthesia rate, and the outstanding cardiac safety question.
Conclusion
Retatrutide represents a genuine pharmacological advance. Its triple-agonist mechanism produces weight loss that exceeds current approved options on efficacy-estimand terms, and the secondary finding of meaningful osteoarthritis pain relief is clinically interesting.
However, the trial data also reveal important limitations:
- Significantly higher discontinuation rates (18.2% at 12 mg vs ~7% for tirzepatide)
- A concerning rate of dysesthesia (20.9% at 12 mg vs 0.4% for tirzepatide)
- Unresolved cardiac arrhythmia signal from the phase 2 trial, awaiting full phase 3 cardiac data
When the analysis shifts from the efficacy estimand to the intention-to-treat figure — which is more reflective of real-world use — the weight loss advantage over tirzepatide shrinks to approximately 3 percentage points. That modest additional efficacy has to be weighed against a meaningfully worse tolerability profile.
Based on current evidence, tirzepatide remains the more balanced and better-tolerated option. Retatrutide may be appropriate for individuals who have not achieved target weight loss with existing therapies, but that clinical decision should wait for full safety data — particularly cardiac outcomes — from the complete phase 3 dataset.
Reference List
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4509428/
- https://www.medclinrese.org/open-access/drug-discovery-and-development-of-semaglutide-and-tirzepatide-from-the-gila-monsters-heloderma-spp.pdf
- https://www.sciencedirect.com/science/article/abs/pii/S2352154616300274
- https://www.ncbi.nlm.nih.gov/sites/books/NBK279127/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC12507501/
- https://www.ncbi.nlm.nih.gov/sites/books/NBK279127/
- https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.868037/full
- https://www.sciencedirect.com/science/article/abs/pii/S014067362301053X
- https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-weight-loss-of-up-to-an-average-of-71-2-lbs-along-with-substantial-relief-from-osteoarthritis-pain-in-first-successful-phase-3-trial-302638804.html
- https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- https://medical.lilly.com/us/products/answers/has-dysesthesia-been-reported-in-patients-taking-mounjaro-tirzepatide-256308
- https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
